Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has granted inducement awards to four new employees. The awards consist of options to purchase 25,602 shares of company common stock at an exercise price of $20.12, matching the closing price on Nasdaq Global Market on December 12, 2024. The options, granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan, will vest 25% on December 12, 2025, followed by three equal annual installments until full vesting on December 12, 2028. The ten-year options were granted under Nasdaq Listing Rule 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC), un'azienda biotecnologica in fase clinica focalizzata sulle terapie cellulari mRNA per le malattie autoimmuni, ha concesso premi di assunzione a quattro nuovi dipendenti. I premi consistono in opzioni per acquistare 25.602 azioni ordinarie della società a un prezzo di esercizio di 20,12 dollari, corrispondente al prezzo di chiusura sul Nasdaq Global Market del 12 dicembre 2024. Le opzioni, concesse nell'ambito del Piano di Premi Incentivi per Assunzioni Modificato e Riassunto del 2018, matureranno il 25% il 12 dicembre 2025, seguite da tre rate annuali uguali fino alla piena maturazione il 12 dicembre 2028. Le opzioni di dieci anni sono state concesse in base alla Regola di Quotazione Nasdaq 5635(c)(4).
Cartesian Therapeutics (NASDAQ: RNAC), una empresa biotecnológica en etapa clínica centrada en terapias celulares de ARNm para enfermedades autoinmunes, ha concedido premios de inducción a cuatro nuevos empleados. Los premios consisten en opciones para comprar 25,602 acciones ordinarias de la compañía a un precio de ejercicio de $20.12, que coincide con el precio de cierre en el Nasdaq Global Market del 12 de diciembre de 2024. Las opciones, otorgadas bajo el Plan de Premios de Incentivo de Inducción Laboral Modificado y Restablecido de 2018 de la compañía, adquirirán un 25% el 12 de diciembre de 2025, seguidas de tres cuotas anuales iguales hasta la plena adquisición el 12 de diciembre de 2028. Las opciones de diez años se otorgaron bajo la Regla de Cotización 5635(c)(4) de Nasdaq.
Cartesian Therapeutics (NASDAQ: RNAC), 자가면역 질환을 위한 mRNA 세포 치료법에 중점을 두고 있는 임상 단계의 생명공학 회사는 네 명의 신입 직원에게 유인 보상을 수여했습니다. 이 보상은 25,602주의 회사 보통주를 $20.12의 행사 가격으로 구매할 수 있는 옵션으로 구성되어 있으며, 이는 2024년 12월 12일 Nasdaq Global Market의 종가와 일치합니다. 이 옵션은 회사의 2018년 수정 및 재작성된 고용 유인 보상 계획에 따라 부여되며, 2025년 12월 12일에 25%가 부여된 후, 완전 부여까지 세 개의 동등한 연간 할부가 이어집니다. 이 10년 옵션은 Nasdaq 상장 규칙 5635(c)(4) 아래에서 부여되었습니다.
Cartesian Therapeutics (NASDAQ: RNAC), une entreprise de biotechnologie en phase clinique axée sur les thérapies cellulaires à ARNm pour les maladies auto-immunes, a accordé des primes d'incitation à quatre nouveaux employés. Les primes consistent en des options d'achat de 25 602 actions ordinaires de la société à un prix d'exercice de $20,12, correspondant au prix de clôture du Nasdaq Global Market du 12 décembre 2024. Les options, accordées dans le cadre du Plan de primes d'incitation à l'emploi modifié et révisé de 2018 de l'entreprise, deviendront acquises à 25 % le 12 décembre 2025, suivies de trois versements annuels égaux jusqu'à complète acquisition le 12 décembre 2028. Les options de dix ans ont été accordées selon la règle d'inscription 5635(c)(4) de Nasdaq.
Cartesian Therapeutics (NASDAQ: RNAC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf mRNA-Zelltherapien für Autoimmunerkrankungen konzentriert, hat vier neuen Mitarbeitern Anreizvergütungen gewährt. Die Vergütungen bestehen aus Optionen zum Kauf von 25.602 Aktien des Unternehmens zu einem Ausübungspreis von 20,12 $, was dem Schlusskurs an der Nasdaq Global Market am 12. Dezember 2024 entspricht. Die Optionen, die im Rahmen des überarbeiteten Anreizvergütungsplans für Beschäftigungsanreize von 2018 des Unternehmens gewährt wurden, erwerben zu 25% am 12. Dezember 2025, gefolgt von drei gleichen jährlichen Raten bis zur vollständigen Ausübung am 12. Dezember 2028. Die zehnjährigen Optionen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- Stock options granted align employee interests with shareholders
- Exercise price set at market value ($20.12) demonstrates fair compensation practice
- None.
FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
How many shares were included in RNAC's December 2024 employee stock options grant?
What is the exercise price for RNAC's December 2024 employee stock options?
What is the vesting schedule for RNAC's December 2024 employee stock options?
How long is the term of RNAC's December 2024 employee stock options?
